Trials / Conditions / Hemoglobinuria, Paroxysmal

Hemoglobinuria, Paroxysmal

15 registered clinical trials studyying Hemoglobinuria, Paroxysmal.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) NCT06903234	Novartis Pharmaceuticals	—
Unknown	Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturn NCT01760096	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Unknown	Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal H NCT01642979	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Unknown	Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobi NCT01224483	Samsung Medical Center	—
Completed	Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria NCT00867932	Alexion Pharmaceuticals, Inc.	Phase 4
Completed	Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States NCT00997386	University of Arizona	Phase 2
Completed	Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloa NCT00975975	Indiana University School of Medicine	Phase 2
Completed	Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors NCT00618969	University of Arizona	Phase 2
Completed	The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) NCT00721864	University of Utah	—
Unknown	Identifying Characteristics of Bone Marrow Failure Syndromes NCT00315419	Office of Rare Diseases (ORD)	—
Completed	Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab NCT00122304	Alexion Pharmaceuticals, Inc.	Phase 3
Completed	Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria NCT00098280	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3
Completed	Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients NCT00122330	Alexion Pharmaceuticals, Inc.	Phase 3
Completed	Stem Cell Transplantation for Patients With Hematologic Malignancies NCT00152139	St. Jude Children's Research Hospital	Phase 3
Approved For Marketing	The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol NCT00438789	Alexion Pharmaceuticals, Inc.	—